



Certificate of Mailing:

The undersigned certifies that this correspondence is being sent via first-class mail, with sufficient postage, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 2nd day of September, 2005.


Linda S. Evans



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Thurmond et al.	Att'y. Docket:	ORT-1489
Serial No.:	09/938,941	Art Unit:	1641
Filed:	24 August 2001	Examiner:	Gailene Gabel
For:	Method Of Monitoring The Effect Of Cathepsin S Inhibitors	Confirmation No.:	2660

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Statement is supplemental to the Information Disclosure Statements dated 21 January 2004 and 25 February 2002. Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, Applicant submits the accompanying Form PTO-1449 citing additional references relating to the above-identified application.

This Statement is being filed under the provisions of 37 C.F.R. § 1.97(c), after the mailing of an initial Office Action on the merits of the RCE. The required statement as specified at 37 C.F.R. § 1.97(e) follows.

The references listed on the enclosed Form PTO-1449 were first cited in a counterpart European application in a Supplementary European Search Report from the European Patent Office not more than three months prior to the filing of this Statement. A copy of the Supplementary European Search Report, with the accompanying EPO Communication dated June 9, 2005, is enclosed.

Copies of the references listed on the enclosed Form PTO-1449 are enclosed. The references are in the English language.

This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that the cited reference qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information more material does not exist.

The Examiner is respectfully requested to initial the citation on the Form PTO-1449 to confirm consideration of the reference.

If any other fees are due in connection with the filing of this Statement, please charge any necessary fees to Deposit Account No. 10-0750.


Respectfully submitted,

Date: September 2, 2005



Linda S. Evans
Reg. No. 33,873

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(858) 320-3406



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. SERIAL NO.
ORT-1489 09/938,941

INFORMATION DISCLOSURE CITATION BY APPLICANT
(Use several sheets if necessary)

APPLICANT
Thurmond et al.

FILING DATE GROUP ART UNIT
24 August 2001 1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	INVENTORS	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY/REGION	CLASS	SUBCLASS	TRANSLATION (if applicable)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Chapman, "Endosomal Proteolysis And MHC Class II Function", <i>Curr. Op. Immunol.</i> , Vol. 10, pp. 93-102 (1998).
	Thurmond et al., "Identification Of A Potent And Selective Noncovalent Cathepsin S Inhibitor", <i>J. Pharmacol. Exp. Ther.</i> , Vol. 308, pp. 268-276 (2004).
	Villadangos et al., "Degradation Of Mouse Invariant Chain: Roles Of Cathepsins S And D And The Influence Of Major Histocompatibility Complex Polymorphism", <i>J. Exp. Med.</i> , Vol. 186, No. 4, pp. 549-560 (1997).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.